Request Demo
Last update 02 Dec 2025
Greziprubart
Last update 02 Dec 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms STSA 1002, STSA-1002 |
Target |
Action inhibitors |
Mechanism C5a inhibitors(complement C5a inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 1120173630H
Source: *****
Sequence Code 1120173631L
Source: *****
Related
7
Clinical Trials associated with GreziprubartNCT07208591
Phase Ⅲ Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
NCT06038916
Phase Ib/II Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
NCT05702983
An Open-label, Single-ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects
100 Clinical Results associated with Greziprubart
Login to view more data
100 Translational Medicine associated with Greziprubart
Login to view more data
100 Patents (Medical) associated with Greziprubart
Login to view more data
100 Deals associated with Greziprubart
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Respiratory Distress Syndrome, Acute | Phase 3 | China | 30 Oct 2025 | |
| Respiratory Distress Syndrome, Adult | Phase 2 | China | 09 Dec 2023 | |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 1 | United States | 31 Jan 2023 | |
| COVID-19 | Phase 1 | United States | 22 Aug 2022 | |
| COVID-19 | Phase 1 | China | 22 Aug 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free